VIDEO: ANX007 may prevent vision loss in patients with geographic atrophy
In this video, Arshad M. Khanani, MD, MA, FASRS, discusses the results of the phase 2 ARCHER trial of ANX007 from Annexon Biosciences in patients with geographic atrophy, presented at the American Academy of Ophthalmology meeting.
In the trial, patients who received the novel neuroprotective agent monthly or every other month were compared with patients who received sham, according to Khanani, director of clinical research at Sierra Eye Associates.
“The primary endpoint was mean change in GA growth, and ANX007 did not achieve that in terms of reducing the lesion area, but what was interesting was, looking at the prespecified secondary endpoint of vision, ANX007 demonstrated significant dose-dependent protection from vision loss,” Khanani said.
“The hope is that this is a neuroprotective agent by blocking C1q in the complement pathway. We may be able to prevent vision loss in patients with geographic atrophy,” he said.
Reference:
- Lally DR. Treatment of geographic atrophy secondary to AMD with intravitreal ANX007, a selective classical complement inhibitor: Results of the ARCHER study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.
Collapse
Healio Interviews
Read more about